Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-03
2007-04-03
Kim, Vickie (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S456000, C514S025000, C514S027000, C424S195110
Reexamination Certificate
active
10185045
ABSTRACT:
The present invention provides a TNF-α production inhibitor containing a kavalactone as an active ingredient, which inhibitor has high safety, exerts an excellent effect of inhibiting TNF-α production, and is useful as a drug or an animal drug for preventing, ameliorating, or treating diseases such as cachexia attributed to cancer or infectious diseases, chronic rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus (SLE), rejection during bone marrow transplantation, multiple organ failure, AIDS, meningitis, hepatitis, and type-II diabetes. The present invention also provides a preventive, ameliorating, or therapeutic agent for diseases caused by abnormal production of TNF-α, the agent containing a kavalactone as an active ingredient.
REFERENCES:
patent: 5296224 (1994-03-01), Schwabe
patent: 5977120 (1999-11-01), Giles, Jr.
patent: 5981496 (1999-11-01), Cohen et al.
patent: 6025363 (2000-02-01), Giles, Jr.
patent: 6143300 (2000-11-01), Stevenot
patent: 6288109 (2001-09-01), Chatterjee et al.
patent: 2001/0031783 (2001-10-01), Steiner
patent: 2002/0077351 (2002-06-01), Asakawa et al.
patent: 2002/0173540 (2002-11-01), Asakawa et al.
patent: 19716 660 (1998-10-01), None
patent: 0 523 591 (1993-01-01), None
patent: 0 664 131 (1995-07-01), None
patent: 1 214 936 (1970-12-01), None
patent: 5-502457 (1993-04-01), None
Fujiki et al., Dietary factors, Cancer detection and prevention online, 200(Jan.-Feb.), vol. 24(supp)/1, Google database.
Fujiki, Hirota, Two stages of Cancer prevention with green tea, J Cancer Res Cli Oncol, 1999, vol. 125, pp. 589-597.
H.J. Meyer, “Antagonistische Wirkungen Geniuner Kawa-Pyrone Bei Experimentellen Entzuendungen Und Fieber”, Klin. Wschr., vol. 43, No. 8, 1965, pp. 469-470, XP-001083832 (w/English Summary).
Archives of Disease in Childhood, vol. 66, pp. 561-562, 1991.
B. Beutler, et al., Nature, vol. 316, pp. 552-551, “Identity of Tumour Necrosis Factor and the Macrophage-Secreted Factor Cachectin”, Aug. 8, 1985.
B. Beutler, et al., Science, vol. 229, pp. 869-871, “Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin”, Aug. 30, 1985.
G. Boonen, et al., Planta Medica, vol. 64, pp. 504-506, “Influence of Genuine Kavapyrone Enantiomers on the GABAA Binding Site”, 1998.
G. Boonen, et al., Planta Medeca, vol. 64, pp. 507-510, “In Vivo Effects of the Kavapyrones (+)- Dihydromethysticine and (±) -Kavain on Dopamine, 3,4-Dihydroxyphenylacetic Acid Serotonin and 5-Hydroxyindoleacetic Acid Levels in Striatal and Coritcal Brain Regions”, 1998.
B.J. Dezube, et al., Journal of Acquired Immune Deficiency Syndromes, vol. 5, No. 11, pp. 1099-1104, Cytokine Dysregulation in Aids: In Vivo Overexpression of MRNA of Tumor Necrosis Factor-Alpha and its Correlation with that of the Inflammatory Cytokine Gro, 1992.
M.J. Elliott, et al., The Lancet, vol. 344, pp. 1105-1110, “Randomised Double-Blind Comparison of Chimeric Monoclonal Antibody to Tumour Necrosis Factor Alpha (CA2) Versus Placebo in Rheumatoid Arthritis”, Oct. 22, 1994.
M.J. Elliott, et al., The Lancet, vol. 344, p. 1125-1127, “Repeated Therapy with Monoclonal Antibody to Tumour Necrosis Factor Alpha (CA2) in Patients with Rheumatoid Arthritis”, Oct. 22, 1994.
H. Fujiki, et al., Proceedings of the Fifty-Eigth Annual Meeting of the Japanese Cancer Association, S11-3, vol. 90, “Cancer Prevention with Drinking Green Tea”, Sep. 29 to Oct. 1, 1999.
G.E. Grau, et al., Science, vol. 237, pp. 1210-1212, “Tumour Necrosis Factor (Cachectin) as an Essential Mediator in Murine Cerebral Malaria”, Sep. 4, 1987.
G.S. Hotamisligil, et al., Science, vol. 259, pp. 87-90, Adipose Expression of Tumour Necrosis Factor-Alpha: Direct Role in Obesity-Linked Insulin Resistance, Jan. 1, 1993.
K. Kanno, Kanzo, vol. 33, pp. 213-217, “Clinical Research on Serum TNF-Alpha in Acute Hepatic Disorders”, Sep. 11, 1991.
T. Matsubara, et al., Clinical Immunology and Immunopathology, vol. 56, pp. 29-36, “Serum Levels of Tumor Necrosis Factor, Interleukin 2 Receptor, and Interferon-Gamma in Kawasaki Disease Involved Coronary-Artery Lesions”, 1990.
C.P.J. Maury, et al., Arthritis and Rheumatism, vol. 32, No. 2, pp. 146-150, “Tumor Necrosis Factor in the Serum of Patients with Systemic Lupus Erythematosus”, Feb. 1989.
F.P. Nestel, et al., J. Exp. Med., vol. 175, pp. 405-413, “Macrophage Priming and Lipoplysaccharade-Triggered Release of Tumor Necrosis Factor Alpha During Graft-Versus-Host Disease”, Feb. 1992.
E.C.C. Rankin, et al., British Journal of Rheumatology, vol. 34, pp. 334-342, “The Therapeutic Effects of An Engineered Human Anti-Tumor Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis”, 1995.
Rinsbroi, vol. 17, No. 10, pp. 2006-2008, “TNF and LT”, 1991.
M.K. Sharief, et al., The New England Journal of Medicine, vol. 325, No. 7, pp. 467-472, “Association Between Tumor Necrosis Factor-Alpha and Disease Progression in Patients with Multiple Sclerosis”, Aug. 15, 1991.
S. Sotheeswaran, Chemistry in Australia, pp. 377-378, Kawa and the Australian Aborigine, Oct. 1987.
H.F. Starnes, Jr., The Journal of Immunology, vol. 145, No. 12, pp. 4185-4191, “Anti-IL-6 Monoclonal Antibodies Protect Against LethalEscherichia coliInfection and Lethal Tumor Necrosis Factor-Alpha Challenge in Mice”, Dec. 15, 1990.
C. Tetta, et al., Annals of the Rheumatic Diseases, vol. 49, pp. 665-667, “Tumor Necrosis Factor in Serum and Synovial Fluid of Patients with Active and Severe Rheumatoid Arthritis”, 1990.
The Journal of Rheumatology, vol. 17, pp. 1107-1108, 1990.
G. Venn, et al., Arthritis and Rheumatism, vol. 36, No. 6, pp. 819-826, “Elevated Synovial Fluid Levels of Interleukin-6 and Tumor Necrosis Factor Associated with Early Experimental canine Osteoarthritis”, Jun. 1993.
A. Waage, et al., The Lancer, vol. 1, pp. 355-357, “Association Between Tumour Necrosis Factor in Serum and Fatal Outcome in Patients with Memingococcal Disease”, Feb. 14, 1987.
Asakawa Yoshinori
Murata Natsuko
Okabe Sachiko
Suma Yukie
Suzuki Hiroto
Kim Vickie
Meiji Dairies Corporation
LandOfFree
TNF-α production inhibitor comprising kavalactone as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TNF-α production inhibitor comprising kavalactone as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TNF-α production inhibitor comprising kavalactone as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3775851